Pfizer Inc., Co. No. 1-3619. (Dec. 31, 2019). Annual Report Form 10-K. SEC Edgar.

https://biontech.de

https://sec.report/CIK/0001776985

https://www.medrxiv.org/content/10.1101/2020.08.17.20176651v2.full....

https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-capital.jpg?resize=300%2C37&ssl=1 300w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 150w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 768w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 1536w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 2048w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 1200w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 640w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 1000w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 1960w, https://i2.wp.com/aim4truth.org/wp-content/uploads/2020/12/wolfe-ca... 2940w" data-lazy-loaded="1" sizes="(max-width: 980px) 100vw, 980px" />

https://sec.report/Document/0001193125-20-198614

Pfizer will fund 100% of the development costs, and we will repay Pfizer our 50% share of these costs if success-based milestones are reached, or with proceeds generated from the commercialization of the vaccine, if approved. If the vaccine program is not successful or does not generate sufficient proceeds, we will not be required to pay back our 50% share of the development costs incurred…

…we and Pfizer would also work jointly to commercialize the vaccine worldwide (excluding China which is covered by our collaboration with Fosun Pharma). https://en.wikipedia.org/wiki/Fosun_Pharmaceutical

…the parent company of fellow listed company Sinopharm Group (Chinese: 国药控股).

https://en.wikipedia.org/wiki/Sinopharm_Group

In April 2020, Sinopharm’s parent company China National Pharmaceutical Group began developing chemically-inactivated whole virus vaccines for COVID-19, whose Phase II results were published in The Lancet and Journal of the American Medical Association respectively.^[5][6] Sinopharm is currently conducting Phase III trials of the vaccine in Argentina^[7], Bahrain^[8], Brazil^[9], Egypt^[10], Jordan^[11], Morocco^[12], Pakistan^[13], Peru^[14], and United Arab Emirates.^[15]

https://en.wikipedia.org/wiki/China_National_Pharmaceutical_Group

China National Pharmaceutical Group Corp. (CNPGC) known as Sinopharm is a Chinese state-owned enterprise

China National Pharmaceutical Group was supervised by the State-owned Assets Supervision and Administration Commission of the....^[5]

https://en.wikipedia.org/wiki/State-owned_Assets_Supervision_and_Ad...

1	State Power Investment Corporation	国家电力投资集团公司
2	China Aerospace Science and Technology Corporation	中国航天科技集团公司
3	China Aerospace Science and Industry Corporation	中国航天科工集团公司
4	Aviation Industry Corporation of China	中国航空工业集团公司
5	China State Shipbuilding Corporation	中国船舶工业集团公司
6	China North Industries Group Corporation	中国兵器工业集团公司
7	China South Industries Group Corporation	中国兵器装备集团公司
8	China Electronics Technology Group	中国电子科技集团公司
9	Aero Engine Corporation of China	中国航空发动机集团有限公司
10	China National Petroleum Corporation	中国石油天然气集团公司

See 11 to 95

BioNTech SE is registered with the U.S. Security and Exchange Commission and incorporated in the state of Germany. BioNTech SE is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by BioNTech SE.

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company’s oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab and does not yet have any commercialized medicines.

PDF, p. 173

https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech-5.jpg?resize=300%2C34&ssl=1 300w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 150w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 768w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 1536w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 2048w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 1200w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 640w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 1000w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/biontech... 1960w" data-lazy-loaded="1" sizes="(max-width: 980px) 100vw, 980px" />

BIONTECH SIGNS COLLABORATION AGREEMENT WITH PFIZER TO DEVELOP MRNA-BASED VACCINES FOR PREVENTION OF INFLUENZA

https://www.businesswire.com/news/home/20180815005735/en/BioNTech-S...

https://fintel.io/so/us/ntgn

Security	NTGN / Neon Therapeutics, Inc. (64050Y100)
President & CEO	O’Dowd Hugh
ISIN	US64050Y1001
LEI	5493002CE5QX7NT6VT20
Institutional Owners	7
Shares Outstanding	28,963,858 shares

PFIZER INVESTORS:

March 13, 2020

Form DEF 14A

Proxy Statement (definitive)

https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.jpg?resize=300%2C10&ssl=1 300w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 150w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 768w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 1536w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 2048w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 1200w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 640w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 1000w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 1960w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/def-14a.... 2940w" data-lazy-loaded="1" sizes="(max-width: 980px) 100vw, 980px" />

https://www.sec.gov/Archives/edgar/data/78003/000093041320000781/c9...

Pfizer Inc., Co. No. 1-3619. (Mar. 13, 2020). Form DEF 14A Proxy Statement, Directors and Officers. SEC Edgar.

PFIZER’S TOP THREE SHAREHOLDERS:

http://d18rn0p25nwr6d.cloudfront.net/CIK-0000078003/e7d7e633-7011-4...

https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/beneficial-owners.jpg?resize=300%2C168&ssl=1 300w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/benefici... 150w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/benefici... 768w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/benefici... 1536w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/benefici... 1200w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/benefici... 640w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/benefici... 893w, https://i0.wp.com/aim4truth.org/wp-content/uploads/2020/12/benefici... 1766w" data-lazy-loaded="1" sizes="(max-width: 980px) 100vw, 980px" />